Overview
Indications
Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting. 2 highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abd
Contraindications
When this intervention should not be used
Ondansetron orally disintegrating tablets are contraindicated in patients: Adverse Reactions (6.2) [see] known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation receiving concomitant apomorphine due to the risk of profound hypotension and loss of
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
116 trials linked to this intervention
Recent Trials
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
Naltrexone Treatment for Alcoholism
Drug Therapy for Alcohol Detoxification
Naltrexone for Relapse Prevention
Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Ondansetron (substance)
- SNOMED CT
- 372487007
- UMLS CUI
- C0061851
- RxNorm CUI
- 26225
- Labeler
- A-S Medication Solutions
Clinical Data
This intervention maps to 3 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.